Shire Exercises Option On Heptares' Preclinical Candidate In $190 Million Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.'s G-protein coupled receptor specialist, Heptares, could receive up to $190 million plus royalties from Shire as it concludes its first product out-licensing agreement.
You may also be interested in...
Heptares And Complix Raise Series B Funds To Advance Preclinical Compounds
GPCR-focused Heptares and the protein scaffold company Complix complete a seemingly rare event for European biotechs, a second round of VC funding.
Cubist Is Latest Heptares Collaborator On GPCR-Targeted Drugs
U.S. acute hospital care specialist Cubist has become the sixth major pharma company to collaborate with U.K.-based Heptares on finding novel therapeutics that interact with G-protein coupled receptors.
Deals Of The Week: Shire/Heptares, NicOx/Altacor, UCB/Oxford University
This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.